Studies showing that injection of some of the key cytokines produced in rheumatic diseases into HC, such as IL-1β or IL-6, produces fatigue and that biologics targeting IL-6 or TNF-α ameliorate fatigue [11, 40–42] suggest a role for these molecules in the development of fatigue. This evidence concerns the gene IL1B and rheumatic disorder.